Articles On Cann Group (ASX:CAN)
Title | Source | Codes | Date |
---|---|---|---|
Crucible: Dr Boreham’s A-To-Z of 2024 biotech
From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose... |
Stockhead | CAN | 5 days ago |
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX Paradigm Biopharmaceuticals rose 151% in Novembe... |
Stockhead | CAN | 2 weeks ago |
ASX cannabis stocks eyeing $1 billion domestic market
The initial buzz surrounding ASX cannabis stocks saw a lot of early investors reap a lot of early profits, while many latecomers lost their shirts. The party started when Canada and the United States moved to legalise not just medicinal can... |
Motley Fool | CAN | 3 weeks ago |
2 ASX cannabis shares with big news today
A few years ago the market was abuzz with excitement over ASX cannabis shares or pot stocks. Since then, the effects have worn off and this side of the market has been getting very little attention. That was until today when two ASX cannabi... |
Motley Fool | CAN | 3 weeks ago |
Dr Boreham’s Crucible: The rise and rise of LTR Pharma
When we were kids eyeing an unobtainable treat or the not-so-imminent arrival of Santa, Mum used to tell us to be patient. Patience, indeed, is a virtue and an admirably quality to exhibit throughout one’s adult life. But there are circumst... |
Stockhead | CAN | 3 weeks ago |
Renerve all set to become only the second nerve-repair stock on the ASX
Nerve-repair company Renerve is set to make its ASX debut today Renerve is developing products for repair and replacement of damaged peripheral nerves It becomes only the second nerve-repair company on the ASX, after Orthocell When Rene... |
Stockhead | CAN | 3 weeks ago |
Closing Bell: ASX swings wildly, Scentre drags and these assets could Trump bump
ASX slipped after early gains, then finished strongly Energy sector helped offset losses; Quickstep, Sigma Healthcare turned heads Wall Street rallied to record highs after Trump’s win The ASX swung from gains, to losses at lunchtime,... |
Stockhead | CAN | 1 month ago |
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | CAN | 1 month ago |
ASX October Winners: The 50 best stocks in weaker month for markets
The S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones Indices said financials led the gains in October and is up 30% YTD Ovanti rose 525% in October after appointment of former Zip US CFO Simon K... |
Stockhead | CAN | 1 month ago |
Health Check: Despite headwinds, Australia’s third force in pharmacy finds prescription for growth
EBOS Group affirms current-year earnings expectations Cannabis stocks report mixed quarterly revenue and earnings trends Atomo Diagnostics gets federal backing for syphilis home test As the competition regulator mulls the proposed $8.8... |
Stockhead | CAN | 1 month ago |
Closing Bell: ASX up but MinRes slumps on lithium downgrade; China stocks also sink
ASX closes higher with consumer and utilities leading the charge Wall Street rally boosts sentiment as Nvidia jumps 4pc China’s CSI 300 index falls 5pc amid doubts over stimulus plans The ASX closed 0.13% higher on Wednesday, thanks... |
Stockhead | CAN | 2 months ago |
HEALTH CHECK: Lion City’s Orthocell approval provides a Singapore Sling-board to Asian markets
Orthocell wins Singaporean approval for its Remplir nerve-repair product Lumos wraps up $10 million whip-round amid surge of raisings in the sector ‘Nice tidy’ Cyclopharm eyes profitability from next year as US revenues grow It’s not th... |
Stockhead | CAN | 2 months ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | CAN | 2 months ago |
ASX September Winners: The 50 best stocks in a strong month for markets
Renewed optimism lifted the S&P/ASX 200 by 3% in September, closing at a record 8,239.20 points S&P Dow Jones Indices said small cap companies outperformed in September, with the materials sector rebounding 13% Mithril Silver and... |
Stockhead | CAN | 2 months ago |
Closing Bell: Sigma soars 22pc, Qantas feels heat from Qatar, and traders cash in on miners’ rally
ASX dips as miners lead selloff as Chinese markets close for holidays Sigma Healthcare soars 22pc after merger update Qantas tumbles 4pc as Qatar eyes Virgin Australia stake The ASX dipped from its record high as miners led the sellof... |
Stockhead | CAN | 2 months ago |
Closing Bell: Another China boost for mining stocks; Odessa soars 150pc on uranium project backing
ASX rises modestly with mining stocks leading gains Fortescue surges nearly 5pc as iron ore prices climb on fresh China stimulus Odessa soars on news of a $1,1m placement to secure exploration at its Lyndon uranium project The ASX scal... |
Stockhead | CAN | 2 months ago |
Closing Bell: Investors rush to mining stocks after China news; while Star crashes 40pc to new low
ASX rises modestly with mining stocks leading gains Fortescue surges nearly 5pc as iron ore prices climb Star Entertainment plunges over 40pc after trading halt lifted The ASX rose modestly by 0.1% on Friday, buoyed by a surge in min... |
Stockhead | CAN | 2 months ago |
Closing Bell: Iron ore giants help ASX to another record; RBA rate cut far-off as job market stays tight
ASX200 hits record high driven by US Fed interest rate cut Mining stocks surge as iron ore prices rebound ALS shares drop 10pc, Monadelphous rises on new contracts The ASX200 hit yet another record high today, boosted by the first inte... |
Stockhead | CAN | 3 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | CAN | 4 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | CAN | 4 months ago |
Weed Week: Getting a grip on the cannabis scene amid a pending regulatory shakeup
The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month The cannabis industry is c... |
Stockhead | CAN | 5 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | CAN | 5 months ago |
ASX June Winners: The best 50 stocks as inflation spikes
S&P/ASX 200 rose 1% in June with large caps leading gains with mid, small and emerging companies lagging S&P/ASX 200 financials and consumer staples were the top performers in June with materials the biggest laggard Urea fertiliser... |
Stockhead | CAN | 5 months ago |
Weed Week: MDMA for PTSD hits roadblock with FDA; and recent ASX cannabis stock winners
FDA panel rejects MDMA for PTSD treatment, citing safety and data concerns Advocates argue MDMA’s benefits outweigh risks, call for further research. South Africa legalises personal cannabis use, setting precedent for African nations G... |
Stockhead | CAN | 6 months ago |
Closing Bell: Aussie shares slip on commodities dip; but Goldies soar on rates hopes
Aussie shares down on weaker commodities Iron ore and energy stocks slip, while goldies gain Intel CEO Pat Gelsingers takes swipe at Nvidia’s CEO Jensen Huang Aussie shares dropped slightly on Tuesday, closing -0.2% lower as the impact... |
Stockhead | CAN | 6 months ago |
Top 10 at 10: Discoveries and a $200m rare earths, mineral sands payday
Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | CAN | 6 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | CAN | 6 months ago |
Cann Group secures funding for next 12 months with $5m lifeline
As Cann Group (ASX: CAN) looks to finally reap the fruits of its capital-intensive $115 million Mildura production and manufacturing facility, the fast-growing medicinal cannabis company has been pulling out all stops to shore up finances a... |
businessnewsaustralia.com | CAN | 7 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | CAN | 7 months ago |
Could ASX cannabis shares be set for a smoking hot rebound?
With a few notable exceptions, ASX cannabis shares widely underperformed again over the last year. That's a far cry from the heady days of 2019 and 2020 when ASX cannabis shares joined their American-listed peers in setting investors' portf... |
Motley Fool | CAN | 7 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | CAN | 7 months ago |
Things you may not know about Made in Australia, and ASX stocks that manufacture right here
Albanese govt announces the Future Made in Australia Act Why supporting Australian Made is a win-win game Stockhead reached out to Australian Made CEO, Ben Lazzaro The ambitiously named Future Made in Australia Act was launched a couple... |
Stockhead | CAN | 7 months ago |
Weed Week: A VAST majority of Americans now want marijuana to be legal
Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month Global weed stocks have been on bumpy ride over the p... |
Stockhead | CAN | 8 months ago |
Cann Group CEO resigns after just 14 months at the helm
Cann Group (ASX: CAN) CEO Peter Koetsier has tendered his resignation just 14 months after assuming leadership of the medicinal cannabis company, which is growing sales at a fast clip but remains burdened by the debts incurred as a result o... |
businessnewsaustralia.com | CAN | 9 months ago |
Playing with fire: The dangers of chasing hot trends
Content Director Patrick Poke of Betashares explores the risks associated with impulsively reacting to investment trends fuelled by media hype, and explain why prudent asset selection, diversification, and maintaining a composed approach ar... |
Rask Media | CAN | 9 months ago |
Weed Week: Cannabis can ‘kill melanoma’; and Germany legalises weed possession
Study shows cannabis can kill melanoma cells Germany has voted to legalise cannabis possession The best performing ASX weed stocks over the past month It hasn’t been a stellar month for global cannabis stocks, with the index falling by... |
Stockhead | CAN | 9 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | CAN | 9 months ago |
Going concerns notices raised for ASX cannabis players Cann Group and Althea
Material uncertainties have been raised about two of the largest medicinal cannabis companies listed on the ASX to continue as going concerns, after Cann Group (ASX: CAN) and Althea Group (ASX: AGH) incurred December half losses of $14.3 mi... |
businessnewsaustralia.com | CAN | 9 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | CAN | 9 months ago |
Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners
Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month There are currently at least 3,000 individ... |
Stockhead | CAN | 10 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | CAN | 1 year ago |
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
Jamaican nettletree is said to contain traces of cannabidiol (CBD) Victoria set to launch a medical cannabis driving trial for patients How ASX weed stocks have performed over the past week and month Scientists in Brazil said they’ve d... |
Stockhead | CAN | 1 year ago |
Weed Week: US House Speaker ousting could boost weed stocks; TGA urged to allow the term ‘medicinal cannabis’
Cannabis stocks could rise after the removal of US House Speaker Montu says TGA has to allow the term ‘medicinal cannabis’ to be used We look at the best performing ASX weed stocks over the past month Some experts believe cannabis stock... |
Stockhead | CAN | 1 year ago |
Weed Week: Big win for cannabis as SAFER Banking Act approved; market remains robust in Australia
Big win for cannabis as SAFER Banking Act set to be passed in the US Australia’s cannabis industry remains robust this year, says TGA We look at how ASX weed stocks have performed over the past weeks A huge win for cannabis as US SAFER... |
Stockhead | CAN | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | CAN | 1 year ago |
Weed Week: Short sellers burned as cannabis stocks stage a rebound. Where to next?
Cannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors is the Section 280E of the US IRS tax code We take a look at the best performing weed stocks in last couple of weeks Having been mauled fo... |
Stockhead | CAN | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | CAN | 1 year ago |
Weed Week: Growing excitement for cannabis stocks after marijuana rescheduling hopes in the US
Cannabis stocks jumped after marijuana rescheduling recommendation in the US Study in Australia shows cannabis is effective on a range of conditions We take a look at the best performing ASX stocks over the past week Cannabis stocks ope... |
Stockhead | CAN | 1 year ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | CAN | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | CAN | 1 year ago |